Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells

Drug Delivery

Volumn 20, Issue 8, 2013, Pages 338-348

  Acevedo Morantes, Claudia Y ^a   Acevedo Morantes, María T ^a,b   Suleiman Rosado, David ^a   Ramírez Vick, Jaime E ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b UNIVERSIDAD DE CARTAGENA   (Colombia)

Author keywords

Behenic acid; Camptothecin; Compritol 888 ATO; Solid lipid nanoparticles; Supercritical fluid technology

Indexed keywords

BEHENIC ACID; CAMPTOTHECIN; GLYCEROL BEHENATE; SOLID LIPID NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CELL STRAIN MCF 10; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; ENCAPSULATION; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; HUMAN; HUMAN CELL; HYDRODYNAMICS; INFRARED SPECTROSCOPY; LIGHT SCATTERING; NANOTECHNOLOGY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; THERMAL ANALYSIS; TREATMENT OUTCOME; X RAY DIFFRACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FATTY ACIDS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LIPIDS; LIPOSOMES; MCF-7 CELLS; NANOPARTICLES; SOLUBILITY; TOPOISOMERASE I INHIBITORS;

EID: 84885661795     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.834412     Document Type: Article

References (52)

1. Botella P, Abasolo I, Fernández Y, et al. (2011). Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation. J Control Rel 156: 246-57.
2. Burke TG, Mishra AK, Wani MC, Wall ME. (1993). Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32: 5352-64. (Pubitemid 23167976)
3. Cansell F, Aymonier C. (2009). Design of functional nanostructured materials using supercritical fluids. J Supercrit Fluids 47: 508-16.
4. Ç irpanli Y, Allard E, Passirani C, et al. (2011). Pharmaceutical nanotechnology antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int J Pharmaceut 403: 201-6.
5. Coates J. (2000). Interpretation of infrared spectra, a practical approach. In: Meyers RA, ed. Encyclopedia of analytical chemistry. Chichester, UK: John Wiley & Sons Ltd, 10815-37.
6. Cocero MJ, Martin A, Mattea F, Varona S. (2009). Encapsulation and co-precipitation processes with supercritical fluids: fundamentals and applications. J Supercrit Fluids 47: 546-55.
7. Giovanella BC. (1997). Topoisomerase I inhibitors. In: Teicher BA, ed. Cancer therapeutics: experimental & clinical agents. Totowa, NJ: Humana Press, 137-52.
8. Gokce EH, Korkmaz E, Tuncay-Tanriverdi S, et al. (2012). A comparative evaluation of coenzyme Q10-loaded liposomes and solid lipid nanoparticles as dermal antioxidant carriers. Int J Nanomed 7: 5109-17.
9. Hatefi A, Amsden B. (2002). Camptothecin delivery system. Pharmac Res 19: 1389-97.
10. Jeha S, Kantarjian H, O'Brien S, et al. (1998). Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia. Leuk Lymphoma 32: 159-64. (Pubitemid 29086393)
11. Jenning V, Thünemann AF, Gohla SH. (2000). Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199: 167-77. (Pubitemid 30236188)
12. Joguparthi V, Xiang TX, Anderson BD. (2008). Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67. J Pharm Sci 97: 400-20.
13. Kalani M, Yunus R. (2011). Application of a supercritical antisolvent method for drug encapsulation: a review. Intl J Nanomed 6: 1429-42.
14. Korsholm KS, Agger EM, Foged C, et al. (2007). The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121: 216-26. (Pubitemid 46663090)
15. Kroll DJ, Rowe TC. (1991). Phosphorylation of DNA topoisomerase II in a human tumor cell line. J Biol Chem 266: 7957-61. (Pubitemid 21906458)
16. Kuo YC, Chung CY. (2011). Solid lipid nanoparticles comprising internal Compritol- 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Colloid Surf B: Biointer 88: 682-90.
17. Lansiaux A, Léonce S, Kraus-Berthier L, et al. (2007). Novel stable Camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs. Mol Pharm 72: 311-19. (Pubitemid 47124111)
18. Lavergne O, Demarguay D, Kasprzyk PG, Bigg DC. (2000). Homocamptothecins: E-ring modified CPT analogues. Ann NY Acad Sci 922: 100-11. (Pubitemid 32050245)
19. Li FQ, Hu JH, Deng JX, et al. (2006). In vitro controlled release of sodium ferulate from Compritol- 888 ATO-based matrix tablets. Int J Pharm 324: 152-7.
20. Lin CH, Al-Suwayeh SA, Hung CF, et al. (2013). Camptothecin-loaded liposomes with a-melanocyte-stimulating hormone enhance cytotoxicity toward and cellular uptake by melanomas: an application of nanomedicine on natural product. J Tradit Comp Med 3: 102-9.
21. Lowry MB, Duchemin AM, Robinson JM, Anderson CL. (1998). Functional separation of pseudopod extension and particle internalization during Fc gamma receptor-mediated phagocytosis. J Exp Med 187: 161-76. (Pubitemid 28060432)
22. Lu AJ, Zheng ZS, Zou HJ, et al. (2007). 3D-QSAR study of 20 (S)-camptothecin analogs. Eur J Med Chem 42: 307-14.
23. Mi Z, Burke TG. (1994). Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33: 10325-36. (Pubitemid 24281798)
24. Min KH, Park K, Kim YS, et al. (2008). Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Rel 127: 208-18.
25. Mo Y, Lim LY. (2005). Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Control Rel 107: 30-42. (Pubitemid 41253700)
26. Morgan MT, Nakanishi Y, Kroll DJ, et al. (2006). Dendrimerencapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res 66: 11913-21. (Pubitemid 46094204)
27. Obaidat AA, Obaidat RM. (2001). Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate. Eur J Pharm Biopharm 52: 231-5. (Pubitemid 32755903)
28. Ozyazici, M, Gökçe EH, Ertan G. (2006). Release and diffusional modeling of metronidazole lipid matrices. Eur J Pharm Biopharm 63: 331-9. (Pubitemid 44218741)
29. Patel NM, Patel NV. (2008). Controlled release of dipyridamole from floating matrices prepared using glyceryl behenate. Drug Deliv Tech 8: 54-9.
30. Patel JK, Patel NV, Shah SH. (2009). In vitro controlled release of colon targeted mesalamine from Compritol- ATO 888 based matrix tablets using factorial design. Res Pharm Sci 4: 63-75.
31. Peikov V, Ugwu S, Parmar M, et al. (2005). pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation. Int J Pharm 299: 92-9. (Pubitemid 40962410)
32. Perez MA, Ghaly ES, Marti A. (1993). Sustained release phenylpropanolamine hydrochloride from Compritol- 888 ATO matrix. Puerto Rico Health Sci J 12: 263-7.
33. Rao MRP, Ranpise AA, Thanki KC, et al. (2009). Effect of processing and sintering on controlled release wax matrix tablets of ketorolac tromethamine. Indian J Pharm Sci 71: 538-44.
34. Rejman J, Conese M, Hoekstra D. (2006). Gene transfer by means of lipo- and polyplexes: role of clathrin and caveolae-mediated endocytosis. J Liposome Res 16: 237-47. (Pubitemid 44358997)
35. Sato K. (1988). Crystallization of fats and fatty acids. In: Garti N, Sato K, eds. Crystallization and polymorphism of fats and fatty acids. Surfactant science series. New York: Marcel Dekker Inc, 267-303.
36. Schmid B, Chung DE, Warnecke A, et al. (2007). Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leulinker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem 18: 702-16. (Pubitemid 47010789)
37. Singh I, Kumaravadivel N, Gnanam R, Vellalkumar S. (2010). RP-HPLC analysis for camptothecin content in Nothapodytes nimmoniana, an endangered medicinal plant. J Med Plants Res 4: 255-9.
38. Souto EB, Mehnert W, Müller RH. (2006). Polymorphic behaviour of Compritol- 888 ATO as bulk lipid and as SLN and NLC. J Microencapsul 23: 417-33.
39. Svenson S, Wolfgang M, Hwang J, et al. (2011). Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J Control Release 153: 49-55.
40. Stevenson JP, DeMaria D, Sludden J, et al. (1999). Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Ann Oncol 10: 339-44. (Pubitemid 29217227)
41. Sun SF. (2004). Physical chemistry of macromolecules: basic principles and issues. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc.
42. Tardi P, Choice E, Masin D, et al. (2000). Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60: 3389-93. (Pubitemid 30482152)
43. Tong R, Cheng J. (2010). Controlled synthesis of camptothecinpolylactide conjugates and nanoconjugate. Bioconjugate Chem 21: 111-21.
44. Uhumwangho MU, Okor RS. (2005). Current trends in the production and biomedical applications of liposomes: a review. J Biomed Sci 4: 9-21.
45. Ulukan H, Swaan PW. (2002). Camptothecins, a review of their chemotherapeutical potential. Drugs 62: 2039-57. (Pubitemid 35204037)
46. Venkata Naga Jyoty N, Muthu Prasana P, Suhas NS, et al. (2010). Microencapsulation techniques, factors influencing encapsulation efficiency. J Microencapsul 27: 187-97.
47. Wall ME, Wani MC. (1996). Camptothecin: discovery to clinic. Ann NY Acad Sci 803: 1-12.
48. Wall ME, Wani MC, Cook CE, et al. (1996). Plant antitumor agents. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J Am Chem Soc 88: 3888-90.
49. Yang SC, Lu LF, Cai Y, et al. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Rel 59: 299-307. (Pubitemid 29238174)
50. Yasuji T, Takeuchi H, Kawashima Y. (2008). Particle design of poorly water-soluble drug substances using supercritical fluid technologies. Adv Drug Deliv Rev 60: 388-98.
51. Zhao X, Zu Y, Li Q, et al. (2010). Preparation and characterization of camptothecin powder micronized by a supercritical antisolvent (SAS) process. J Supercrit Fluids 51: 412-19.
52. Zhou W, Yuan X, Wilson A, et al. (2002). Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjugate Chem 13: 1220-5. (Pubitemid 35420013)